Imbed Biosciences' DualGuard™ Silver-Gallium Matrix Safety Study Now Registered on ClinicalTrials.gov
Study Registration (NCT07695688) Supports Imbed's Ongoing Effort to Address Biofilm — a Persistent Challenge Across Wound Care and Beyond MIDDLETON, Wis., Oct. 1, 2026 /PRNewswire/ -- Imbed Biosciences, developer of the SAMatrix™ (Synthetic Antimicrobial Matrix) technology platform, today...
Short extract only — this publisher licenses its text. Read the full release at the source.
More from Commercial newswire
- The Visioneers with Zay Harding Renewed for Two More Seasons on CBS
- Maxwell Power Secures an additional $800 Million from Fairtide Partners
- ICIMS Customers Rate Platform Above Talent Acquisition Vendor Average Across 12 Categories in 2026 IDC SaaS Customer Satisfaction Award
The rest of this wire is for subscribers
Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
7 days, no card required.
Read releases like this the second they cross the wire.
1,400+ feeds — live on PPN World right now. Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live here.
PPN Source →